Merus N.V. (NASDAQ:MRUS) COO Sells $368,225.00 in Stock

Merus N.V. (NASDAQ:MRUS - Get Free Report) COO Peter B. Silverman sold 6,695 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $55.00, for a total transaction of $368,225.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Peter B. Silverman also recently made the following trade(s):

• On Thursday, July 10th, Peter B. Silverman sold 16,805 shares of Merus stock. The shares were sold at an average price of $55.00, for a total transaction of $924,275.00.
• On Friday, June 20th, Peter B. Silverman sold 34,000 shares of Merus stock. The shares were sold at an average price of $52.76, for a total transaction of $1,793,840.00.

Merus Stock Up 2.1%

NASDAQ:MRUS traded up $1.12 during mid-day trading on Monday, reaching $55.62. 694,277 shares of the company were exchanged, compared to its average volume of 732,623. Merus N.V. has a 12 month low of $33.19 and a 12 month high of $62.98. The stock has a market cap of $3.85 billion, a PE ratio of -13.63 and a beta of 1.00. The company has a fifty day moving average of $50.76 and a 200 day moving average of $45.66.

Merus (NASDAQ:MRUS - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative net margin of 506.73% and a negative return on equity of 35.99%. The business had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. On average, equities research analysts anticipate that Merus N.V. will post -3.85 EPS for the current fiscal year.

Analysts Set New Price Targets

MRUS has been the topic of several analyst reports. Wall Street Zen raised shares of Merus from a "sell" rating to a "hold" rating in a report on Saturday. Guggenheim reaffirmed a "buy" rating and issued a $109.00 target price on shares of Merus in a report on Friday, March 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $75.00 target price on shares of Merus in a report on Monday, May 19th. Wells Fargo & Company lowered their target price on shares of Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Finally, William Blair reaffirmed an "outperform" rating on shares of Merus in a report on Monday, April 28th. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Merus presently has an average rating of "Buy" and an average target price of $84.64.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. FMR LLC raised its position in shares of Merus by 0.4% in the 4th quarter. FMR LLC now owns 6,899,521 shares of the biotechnology company's stock valued at $290,125,000 after acquiring an additional 25,595 shares during the period. Wellington Management Group LLP raised its position in shares of Merus by 34.9% in the 1st quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock valued at $198,588,000 after acquiring an additional 1,220,519 shares during the period. Paradigm Biocapital Advisors LP raised its position in shares of Merus by 99.4% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock valued at $141,831,000 after acquiring an additional 1,679,777 shares during the period. Avoro Capital Advisors LLC raised its position in shares of Merus by 56.8% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock valued at $89,356,000 after acquiring an additional 770,000 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in shares of Merus in the 4th quarter valued at approximately $79,895,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.